Boehringer Ingelheim

Clearside Biomedical Announces First Quarter 2024 Financial Results and Provides Corporate Update

Retrieved on:

木曜日, 5月 9, 2024

ALPHARETTA, Ga., May 09, 2024 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (Nasdaq: CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space (SCS®), today reported financial results for the first quarter ended March 31, 2024, and provided a corporate update.

Key Points:

ET -
ALPHARETTA, Ga., May 09, 2024 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (Nasdaq: CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space (SCS®), today reported financial results for the first quarter ended March 31, 2024, and provided a corporate update.
License and other revenue for the first quarter of 2024 was $230,000, compared to $4,000 for the first quarter of 2023.
Other expense for the first quarter of 2024 was $1.5 million, compared to $0 for the first quarter of 2023.
Clearside’s management will host a webcast and conference call today at 4:30 p.m. Eastern Time to discuss the financial results and provide a corporate update.

Surrozen Provides First Quarter 2024 Financial Results and Business Update

Retrieved on:

水曜日, 5月 8, 2024

Respiratory Research, Telecanthus, Liver disease, Boehringer Ingelheim, Publication, Research, Partnership, Development, Administration, ARVO, Therapy, Pulmonary fibrosis, Retina, Patient, Liver, Eye, Fibrosis, Regeneration, SWAP

SOUTH SAN FRANCISCO, Calif., May 08, 2024 (GLOBE NEWSWIRE) -- Surrozen, Inc. (“Surrozen” or the “Company”) (Nasdaq: SRZN), a company pioneering targeted therapeutics that selectively activate the Wnt pathway for tissue repair and regeneration, today provided first quarter 2024 financial results and business updates.

Key Points:

Financial Results for the First Quarter Ended March 31, 2024
Cash Position: Cash and cash equivalents were $27.3 million as of March 31, 2024, compared to $36.0 million as of December 31, 2023.
However, inclusive of proceeds from a financing completed in April 2024, the proforma cash for March 31, 2024 would be $43.2M.
Restructuring: Restructuring charges for the first quarter ended March 31, 2024 were zero, as compared to $1.2 million for the same period in 2023.
Net Loss: Net loss for the first quarter ended March 31, 2024 was $8.8 million, as compared to $14.3 million for the same period in 2023.

Boehringer Ingelheim shares positive results from the first study worldwide in diabetic macular ischemia

Retrieved on:

月曜日, 5月 6, 2024

Boehringer Ingelheim today presented positive data from the HORNBILL Phase I/IIa study of BI 764524, the first ever study exploring a potential treatment for people living with diabetic macular ischemia (DMI).

Key Points:

Boehringer Ingelheim today presented positive data from the HORNBILL Phase I/IIa study of BI 764524, the first ever study exploring a potential treatment for people living with diabetic macular ischemia (DMI).
The current standard of care for advanced DR includes intravitreal anti-VEGF treatment or invasive laser treatment.
“Retinal non-perfusion is a key driver of vision loss in people living with diabetic retinopathy.
However, until the HORNBILL study, retinal non-perfusion has not been explored as a potential treatment target.”
“Vision loss associated with retinal conditions such as diabetic retinopathy and DMI has a devastating impact on quality of life.

Dr. Reginald Seeto Appointed as CEO and President, to Lead Scipher Medicine's Next Phase of Growth

Retrieved on:

木曜日, 5月 9, 2024

Scipher Medicine, an AI-enabled precision immunology company, today announced the appointment of Reginald Seeto, MBBS*, as Chief Executive Officer and President.

Key Points:

Scipher Medicine, an AI-enabled precision immunology company, today announced the appointment of Reginald Seeto, MBBS*, as Chief Executive Officer and President.
Dr. Seeto is a seasoned CEO and Board Member who brings more than two decades of leadership experience across both diagnostic and therapeutic companies.
Dr. Seeto was most recently the CEO and President of CareDx ("CDNA"), a company focused on the transplant patient.
Seeto and Muir’s appointment mark a significant step forward for Scipher as the company positions itself for continued growth within the field of precision immunology.

Klick Health Wraps First Round of $1,000,000 Klick AI Prize, Awarding First $200,000 to Three Teams

Retrieved on:

火曜日, 5月 7, 2024

One of these entries, a unique, personalized AI training idea for pharma sales reps, was developed by some Client Success team members.

Key Points:

One of these entries, a unique, personalized AI training idea for pharma sales reps, was developed by some Client Success team members.
Round two of the Klick Prize is now open and the judges will reconvene this summer.
Today’s news is the latest in the company’s ongoing AI and machine-learning innovations created to help Klick clients and team members achieve even greater success..
At the prestigious NeurIPS conference in December, it unveiled LOVENet TM , an AI framework that rapidly identifies new uses for existing drugs.

Trialbee to Showcase Power of Data-Driven Clinical Trial Recruitment During Upcoming Webinars and Conferences

Retrieved on:

水曜日, 5月 8, 2024

WILMINGTON, Del., and MALMÖ, Sweden, May 8, 2024 /PRNewswire-PRWeb/ -- Trialbee, the global leader in technology-driven patient recruitment for clinical trials, will host two webinars and participate in three industry conferences in May to showcase its data-driven, personalized approach to identifying and engaging participants for research studies.

Key Points:

For more information and to register…
"Improve Site Pull-Through of Global Patient Referrals."
On May 15 at 10am ET, join Trialbee Director of Customer Delivery Sarah Evans and Product Manager Oskar Daniel to dive into recruitment funnels and demonstrate how data from a centralized Patient Recruitment Platform (PRP) results in high-quality, motivated patients being referred to clinical trial sites.
Trialbee is changing global patient recruitment with the Honey Platform™, a vendor-agnostic and stand-alone platform that provides unprecedented transparency, actionable data insights, and reliable return-on-investment (ROI) reporting.
For more information about how Trialbee is revolutionizing the patient recruitment ecosystem through technology, people, and passion, visit https://www.trialbee.com/ .

Boehringer Ingelheim receives Health Canada approval for SENVELGO™, the once-daily liquid oral solution for newly diagnosed diabetes in cats

Retrieved on:

火曜日, 5月 7, 2024

SENVELGO™ (velagliflozin oral solution) is the first once-daily liquid oral solution to improve glycemic control in newly diagnosed cats with diabetes mellitus.

Key Points:

SENVELGO™ (velagliflozin oral solution) is the first once-daily liquid oral solution to improve glycemic control in newly diagnosed cats with diabetes mellitus.
SENVELGO™ is the first once-daily liquid oral solution for the reduction of hyperglycemia in cats with non-insulin-dependent diabetes mellitus.
Pet owners can give the once-daily liquid oral solution with a small amount of food or directly into the cat's mouth.
Dr. Walt Ingwersen, Technical Services Veterinarian with Boehringer Ingelheim Canada, said SENVELGO™ revolutionizes the treatment and management of feline diabetes in newly diagnosed cats.

Boehringer Ingelheim Unveils New R&D Laboratory in St. Joseph, Mo., Pioneering the Future of Animal Health Products

Retrieved on:

金曜日, 5月 3, 2024

Health, Animal, Heart, Boehringer, Horse, Research, Livestock, Boehringer Ingelheim, Corridor, Fine chemical

ST. JOSEPH, Mo., May 3, 2024 /PRNewswire/ -- Boehringer Ingelheim, a global leader in animal health, celebrated a new and innovative laboratory space at its St. Joseph, Mo.

Key Points:

ST. JOSEPH, Mo., May 3, 2024 /PRNewswire/ -- Boehringer Ingelheim, a global leader in animal health, celebrated a new and innovative laboratory space at its St. Joseph, Mo.
This state-of-the-art facility is set to revolutionize the development of future products, including biotherapeutics.
This location is primarily dedicated to the product development and production of animal health products for livestock and horses.
"Boehringer Ingelheim is not just a global leader in animal health – they are a part of the fabric of our community," said Kim Young, President KC Animal Health Corridor.

US FDA approves high-concentration, citrate-free formulation of Cyltezo® (adalimumab-adbm) injection, Boehringer Ingelheim's interchangeable* biosimilar to Humira®

Retrieved on:

水曜日, 5月 1, 2024

FDA, Ulcerative colitis, Crohn's disease, Arthritis, Boehringer Ingelheim, News, Food, Patient, Psoriasis, National Psoriasis Foundation, Arthritis Foundation, Clinical trial, Pharmaceutical industry

"Many patients are treated with high-concentration adalimumab formulations, and we are excited to add this new option to our approved citrate-free Cyltezo and Adalimumab-adbm offerings."

Key Points:

"Many patients are treated with high-concentration adalimumab formulations, and we are excited to add this new option to our approved citrate-free Cyltezo and Adalimumab-adbm offerings."
"The flexibility of having multiple biosimilar formulations to choose from is important to support broader patient access to biologic medicines."
"We welcome the introduction of this additional formulation to expand the array of options available to our community."
The FDA approval is based, in part, on data from clinical trial VOLTAIRE-HCLF , a Phase I clinical trial comparing the bioavailability of high-concentration and low-concentration formulations of adalimumab-adbm.

ArisGlobal Helps Boehringer Ingelheim Transform Safety Signal Processing by Leveraging Latest LifeSphere Solutions

Retrieved on:

水曜日, 5月 1, 2024

Boehringer Ingelheim, Safety, Risk management, Automation, Patient safety, Patient, RWD, Access, CIO, Generative

BOSTON, May 1, 2024 /PRNewswire/ -- ArisGlobal, a market leader in Life Sciences technology and the creator of LifeSphere®, announced today that research-driven global pharmaceutical company Boehringer Ingelheim is adopting the transformative new functionality of LifeSphere® Clarity™.

Key Points:

Boehringer Ingelheim's own patient safety teams created an on-premise advanced signal detection technology.
ArisGlobal acquired the technology in 2023, and has continued to develop the product, most notably transitioning the offering to the cloud under the name LifeSphere Clarity.
Dr. Robert Buchberger, Sr. VP Patient Safety and Pharmacovigilance at Boehringer Ingelheim, said, "We are very proud of the original signals innovation, developed in-house at Boehringer Ingelheim.
Clarity, as with the wider LifeSphere portfolio, helps biopharma companies expedite critical R&D processes and deliver more for patients, through advanced, efficient risk management."